These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 18768222)

  • 1. Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review.
    Konnopka A; Leichsenring F; Leibing E; König HH
    J Affect Disord; 2009 Apr; 114(1-3):14-31. PubMed ID: 18768222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-of-illness studies and cost-effectiveness analyses in eating disorders: a systematic review.
    Stuhldreher N; Konnopka A; Wild B; Herzog W; Zipfel S; Löwe B; König HH
    Int J Eat Disord; 2012 May; 45(4):476-91. PubMed ID: 22294558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis.
    Konnopka A; König H
    Pharmacoeconomics; 2020 Jan; 38(1):25-37. PubMed ID: 31646432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder.
    Ikic V; Belanger C; Bouchard S; Gosselin P; Langlois F; Labrecque J; Dugas MJ; Marchand A
    J Ment Health Policy Econ; 2017 Mar; 20(1):11-20. PubMed ID: 28418834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of short-term psychodynamic psychotherapy and solution-focused therapy in the treatment of depressive and anxiety disorders during a one-year follow-up.
    Maljanen T; Paltta P; Harkanen T; Virtala E; Lindfors O; Laaksonen MA; Knekt P;
    J Ment Health Policy Econ; 2012 Mar; 15(1):13-23. PubMed ID: 22611089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental benefits and cost of coordinated anxiety learning and management for anxiety treatment in primary care.
    Joesch JM; Sherbourne CD; Sullivan G; Stein MB; Craske MG; Roy-Byrne P
    Psychol Med; 2012 Sep; 42(9):1937-48. PubMed ID: 22152230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.
    Bereza BG; Machado M; Einarson TR
    Clin Ther; 2009 Jun; 31(6):1279-308. PubMed ID: 19695395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of interventions for treating anxiety disorders: A systematic review.
    Ophuis RH; Lokkerbol J; Heemskerk SC; van Balkom AJ; Hiligsmann M; Evers SM
    J Affect Disord; 2017 Mar; 210():1-13. PubMed ID: 27988373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economics of medically unexplained symptoms: a systematic review of the literature.
    Konnopka A; Schaefert R; Heinrich S; Kaufmann C; Luppa M; Herzog W; König HH
    Psychother Psychosom; 2012; 81(5):265-75. PubMed ID: 22832397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-of-illness studies of depression: a systematic review.
    Luppa M; Heinrich S; Angermeyer MC; König HH; Riedel-Heller SG
    J Affect Disord; 2007 Feb; 98(1-2):29-43. PubMed ID: 16952399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders.
    Issakidis C; Sanderson K; Corry J; Andrews G; Lapsley H
    Psychol Med; 2004 Jan; 34(1):19-35. PubMed ID: 14971624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epidemiology of anxiety disorders: prevalence and societal costs.
    Lépine JP
    J Clin Psychiatry; 2002; 63 Suppl 14():4-8. PubMed ID: 12562112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder.
    Beesdo K; Pine DS; Lieb R; Wittchen HU
    Arch Gen Psychiatry; 2010 Jan; 67(1):47-57. PubMed ID: 20048222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of the association of anxiety with health care utilization and costs in people aged 65 years and older.
    Hohls JK; König HH; Raynik YI; Hajek A
    J Affect Disord; 2018 May; 232():163-176. PubMed ID: 29494900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of anxiety disorders to remission.
    Ballenger JC
    J Clin Psychiatry; 2001; 62 Suppl 12():5-9. PubMed ID: 11430617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of self-management interventions for panic disorders, phobias and obsessive-compulsive disorders.
    Barlow JH; Ellard DR; Hainsworth JM; Jones FR; Fisher A
    Acta Psychiatr Scand; 2005 Apr; 111(4):272-85. PubMed ID: 15740463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human and economic burden of generalized anxiety disorder.
    Hoffman DL; Dukes EM; Wittchen HU
    Depress Anxiety; 2008; 25(1):72-90. PubMed ID: 17146763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study.
    Dold M; Bartova L; Souery D; Mendlewicz J; Serretti A; Porcelli S; Zohar J; Montgomery S; Kasper S
    J Psychiatr Res; 2017 Aug; 91():1-13. PubMed ID: 28284107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year course trajectories of anxiety disorders: do DSM classifications matter?
    Batelaan NM; Rhebergen D; Spinhoven P; van Balkom AJ; Penninx BW
    J Clin Psychiatry; 2014 Sep; 75(9):985-93. PubMed ID: 24912140
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.